Remdesivir given ’emergency approval’ to treat COVID-19 in the US

US regulators will allow experimental drug remdesivir to be used on seriously ill COVID-19 patients.

US President Donald Trump announced the news alongside Food and Drug Administration Commissioner Stephen Hahn, who said the drug would be available for patients receiving hospital treatment for COVID-19.

A government-sponsored study has showed that remdesivirshortened recovery time by 31% – about four days on average – for patients in hospital with the virus.

Coronavirus: Infection numbers in real time

Coronavirus: Infection numbers in real time

The study of 1,063 patients is the largest of remdesivir, which belongs to Gilead Sciences.

It found that those given the drug were able to leave hospital in 11 days on average, compared with 15 days for the control group.

It is not yet clear whether remdesivir is preventing COVID-19 deaths but it is the first drug to show promise in fighting COVID-19, which has killed more than 235,000 people worldwide.

Remdesivir has been authorised by the Food and Drug Administration under its emergency powers.

More from Covid-19

  • Coronavirus: Trial begins to see if plasma from COVID-19 survivors can fight the virus

  • Coronavirus: Justin Bieber and Ariana Grande record COVID-19 charity duet

  • Coronavirus: Premier League planning to resume in June at ‘neutral’ stadiums

  • Coronavirus: Ireland announces five-stage exit plan from May to August

  • Coronavirus: Government hits testing target – but critics say figures manipulated

  • Coronavirus: We’re all in this together – but some more than others

Normally, “substantial evidence – usually in the form of more studies – would be required to prove the drug’s safety and effectiveness.

But, due to the pandemic, the FDA only requires a drug maker to prove that the drug’s potential benefits outweigh its risks.

It will still need full approval but the FDA can give this if Gilead Sciences or other researchers provide more evidence of remdesivir’s safety and effectiveness.

The drug, which is given intravenously in hospital, has not been tested on people with the milder form of the virus.

COVID-19: The race for the vaccine

COVID-19: The race for the vaccine

Cathy Burgess, a lawyer specialising in FDA issues, said: “This is a very, very early stage so you wouldn’t expect to have any sort of full approval at this point.

“But obviously they want to get this out to patients as quickly as possible.”

The news comes as Mr Trump said he was hoping for fewer than 100,000 US deaths from the coronavirus, more than the 60,000 to 70,000 he had talked about on Monday.


April: Gilead – drugs trials ‘starting to show some results’

Gilead Sciences chief executive Daniel O’Day called the move an important first step and said the company was donating 1.5 million vials of the drug.

Late in March the FDA authorised malaria drug, hydroxychloroquine, for emergency use after Mr Trump repeatedly touted it as a cure.

But no studies have shown it to work and some have even shown significant safety concerns.

In April, the regulator warned doctors against prescribing it aside from in hospital or for research, due to the risk of those side effects.

Mark Gibson

Graduates in Northwestern University, Evanston, Illinois 1990. Move to Los Angeles California in 2004. Specialized in Internet journalism.

Leave a Reply

Your email address will not be published. Required fields are marked *